Effects of in vitro azithromycin treatment on bronchial epithelial antiviral immunity in asthma phenotypes
Our data suggest that <i>in vitro</i>, AZM works primarily by improving bronchial epithelial antiviral resistance by increasing interferons independent of eosinophilia and atopy status, highlighting the broad applicability of AZM in modulating antiviral immunity in asthma as well as the need for identifying predictors of AZM response beyond inflammatory phenotypes.
Authors
- Asger Sverrild (ORCID: https://orcid.org/0000-0003-0625-6405)
- Lena Uller (ORCID: https://orcid.org/0000-0003-1842-148X)
- Mandy Menzel (ORCID: https://orcid.org/0000-0003-1286-2022)
- Nihaya Mahmoud Said
- Helle Frost Andreassen
- Muzhda Ghanizada (ORCID: https://orcid.org/0000-0001-5535-0380)
- Thérèse Lapperre (ORCID: https://orcid.org/0000-0002-5176-0101)
- Sofia Malm Tillgren
- Samuel Cerps
- Nanna Dyhre‐Petersen (ORCID: https://orcid.org/0000-0002-9794-2955)
- Sisse B. Ditlev (ORCID: https://orcid.org/0000-0003-4417-9711)
- Celeste Porsbjerg (ORCID: https://orcid.org/0000-0003-4825-9436)
- Louis Praeger‐Jahnsen
Institutions
- University of Antwerp (BE)
- Lund University (SE)
- Frederiksberg Hospital (DK)
- Bispebjerg Hospital (DK)
- Antwerp University Hospital (BE)
Publication Details
- Journal
- Frontiers in Allergy
- Published
- 2025-06-17
- DOI
- https://doi.org/10.3389/falgy.2025.1605109
- Citations
- 2
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.33
Funders
- Novo Nordisk
- Vetenskapsrådet